CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $448,182 | +134.7% | 15,070 | +42.2% | 0.00% | +100.0% |
| Q2 2023 | $190,994 | +9.0% | 10,599 | -2.9% | 0.00% | 0.0% |
| Q1 2023 | $175,279 | -9.8% | 10,914 | +2.8% | 0.00% | 0.0% |
| Q4 2022 | $194,291 | -2.9% | 10,617 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $200,000 | +6.4% | 10,178 | +1.0% | 0.00% | 0.0% |
| Q2 2022 | $188,000 | -23.9% | 10,078 | +15.9% | 0.00% | 0.0% |
| Q4 2021 | $247,000 | – | 8,693 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |